dr. (Marc) M.A. Koopmanschap

All publications (178)

• Article (147)

  • Scholarly Publication (134)

    • J. Hermans, M. Reijman, L.M.A. Goossens, H. Verburg, S.M.A. Bierma-Zeinstra & M.A. Koopmanschap (2018). Cost-Utility Analysis of High Molecular Weight Hyaluronic Acid for Knee Osteoarthritis in Everyday Clinical Care in Patients at a Working Age: An Economic Evaluation of a Randomized Clinical Trial. Arthritis Care & Research, 70 (1), 89-97. doi: 10.1002/acr.23242
    • N.J.S. Patty, M.A. Koopmanschap & K.M. Holtzer-Goor (2018). A cost-effectiveness study of ICT training among the visually impaired in the Netherlands. BMC OPHTHALMOLOGY, 18 (98). doi: 10.1186/s12886-018-0761-y
    • J. Hermans, M. Reijman, L.M.A. Goossens, H. Verburg, S.M.A. Bierma-Zeinstra & M.A. Koopmanschap (2017). A cost utility analysis of high molecular weight hyaluronic acid for knee osteoarthritis in everyday clinical care. Arthritis Care & Research. doi: 10.1002/acr.23242
    • M. Schreijenberg, P.A.J. Luijsterburg, Y.D.M. van Trier, D. Rizopoulos, M.A. Koopmanschap, L. Voogt, C. Maher & B.W. Koes (2017). Efficacy of paracetamol, diclofenac and advice for acute low back pain in general practice: design of a randomized controlled trial (PACE Plus). BioMed Central, 18:56. doi: 10.1186/s12891-017-1432-5
    • H.P.A. van der Aa, G. van Rens, F. Verbraak, M. Bosscha, M.A. Koopmanschap, H.C. Comijs, P. Cuijpers & R.M.A. van Nispen (2017). Economic evaluation of an e-mental health intervention for patients with retinal exudative diseases who receive intraocular anti-VEGF injections (E-PsEYE): protocol for a randomised controlled trial. BMJ Open, 7 (11):e018149. doi: 10.1136/bmjopen-2017-018149
    • K.M. Holtzer - Goor, E.J. van Vliet, E. van Sprundel, T. Plochg, M.A. Koopmanschap, N. Klazinga & H. Lemij (2016). Shared Care in Monitoring Stable Glaucoma Patients: A Randomized Controlled Trial. Journal of Glaucoma, 25 (4), E392-E400. doi: 10.1097/ijg.0000000000000335
    • P. Hanly, M.A. Koopmanschap & L. Sharp (2016). Valuing productivity costs in a changing macroeconomic environment: the estimation of colorectal cancer productivity costs using the friction cost approach. European Journal of Health Economics (HEPAC). doi: 10.1007/s10198-015-0698-5
    • S.S. Tan, CH Teirlinck, J. Dekker, L.M.A. Goossens, A.M. Bohnen, J.A.N. Verhaar, P.P. van Es, B.W. Koes, S. Bierma-Zeinstra, P.A.J. Luijsterburg & M.A. Koopmanschap (2016). Cost-utility of exercise therapy in patients with hip osteoarthritis in primary care. Osteoarthritis and Cartilage, 24 (4), 581-588. doi: 10.1016/j.joca.2015.11.010
    • CH Teirlinck, P.A.J. Luijsterburg, J. Dekker, A.M. Bohnen, J.A.N. Verhaar, M.A. Koopmanschap, P.P. van Es, B.W. Koes & S.M.A. Bierma-Zeinstra (2016). Effectiveness of exercise therapy added to general practitioner care in patients with hip osteoarthritis: a pragmatic randomized controlled trial. Osteoarthritis and Cartilage, 24 (1), 82-90. doi: 10.1016/j.joca.2015.07.023
    • W. Boon, L. Martins & M.A. Koopmanschap (2015). Governance of conditional reimbursement practices in the Netherlands. Health Policy, 119, 180-185. doi: 10.1016/j.healthpol.2014.10.013
    • K. Freijer, I. Lenoir-Wijnkoop, C.A. Russell, M.A. Koopmanschap, H.M. Kruizenga, S.K. Lhachimi, K. Norman, M.J.C. Nuijten & J.M.G.A. Schols (2015). The view of European experts regarding health economics for medical nutrition in disease related malnutrition. European Journal of Clinical Nutrition, 69 (5), 539-545. doi: 10.1038/ejcn.2014.280
    • C.A.M. Boumans, H.M. Krol, J.L. Severens, M.A. Koopmanschap, W.B.F. Brouwer & L. Hakkaart-van Roijen (2015). The iMTA Productivity Cost Questionnaire A Standardized Instrument for Measuring and Valuing Health-Related Productivity Losses. Value in Health, 18, 753-758. doi: 10.1016/j.jval.2015.05.009
    • J.C. Bouvy, M. de Bruin & M.A. Koopmanschap (2015). The epidemiology of adverse drug reactions (ADRs) in Europe: A review of recent observational studies. Drug Safety, 38 (5), 437-453. doi: 10.1007/s40264-015-0281-0
    • K.J.E. Asmus, L.E. Flinterman, M.A. Koopmanschap, A.P. Nieboer, T.J. Bakker, J.P. Mackenbach & E.W. Steyerberg (2015). Evaluation of the Prevention and Reactivation Care Program (PReCaP) for the hospitalized elderly: a prospective nonrandomized controlled trial. Clinical Interventions in Aging, 10, 649-661. doi: 10.2147/CIA.S77677
    • C.A.M. de Meijer, P.L.H. Bakx, M.A. Koopmanschap & E.K.A. van Doorslaer (2015). Explaining Declining Rates of Institutional LTC Use in the Netherlands: A Decomposition Approach. Health Economics, 24 (S1), 18-31. doi: 10.1002/hec.3114
    • M.G. Franken, E.A. Stolk, T. Scharringhausen, A. de Boer & M.A. Koopmanschap (2015). A comparative study of the role of disease severity in drug reimbursement decision making in four European countries. Health Policy, 119 (2), 195-202. doi: 10.1016/j.healthpol.2014.10.007
    • P. Makai, W.B.F. Brouwer, M.A. Koopmanschap, E.A. Stolk & A.P. Nieboer (2014). Quality of life instruments for economic evaluations in health and social care for older people: A systematic review. Social Science & Medicine, 102, 83-93. doi: 10.1016/j.socscimed.2013.11.050
    • K.J.E. Asmus, M.A. Koopmanschap, L.E. Flinterman, T.J.E.M. Bakker, J.P. Mackenbach & E.W. Steyerberg (2014). Formal and informal care costs of hospitalized older people at risk of poor functioning: A prospective cohort study. Archives of Gerontology and Geriatrics, 59 (2), 382-392. doi: 10.1016/j.archger.2014.04.014
    • M.G. Franken, M.A. Koopmanschap & A. Steenhoek (2014). Health economic evaluations in reimbursement decision making in the Netherlands: Time to take it seriously? Elsevier, 108 (7), 383-389. doi: 10.1016/j.zefq.2014.06.016
    • J.C. Bouvy, H. Ebbers, H. Schellekens & M.A. Koopmanschap (2013). The cost-effectiveness of periodic safety update reports for biologicals in Europe. Clinical Pharmacology & Therapeutics, 93 (5), 433-442. doi: 10.1038/clpt.2013.13
    • C.A.M. de Meijer, O.A. O'Donnell, M.A. Koopmanschap & E.K.A. van Doorslaer (2013). Health expenditure growth: Looking beyond the average through decomposition of the full distribution. Journal of Health Economics, 32, 88-105. doi: 10.1016/j.jhealeco.2012.10.009
    • M.G. Franken, F. Nilsson, F.G. Sandmann, A. de Boer & M.A. Koopmanschap (2013). Unravelling Drug Reimbursement Outcomes: A Comparative Study of the Role of Pharmacoeconomic Evidence in Dutch and Swedish Reimbursement Decision Making. Pharmacoeconomics (Print), 31 (9), 781-797. doi: 10.1007/s40273-013-0074-1
    • C.A.M. de Meijer, B. Wouterse, J. Polder & M.A. Koopmanschap (2013). The effect of population aging on health expenditure growth: a critical review. European Journal of Ageing, 10 (4), 353-361. doi: 10.1007/s10433-013-0280-x
    • J.C. Bouvy, P.S.S. Fransen, S.A. Baeten, M.A. Koopmanschap, L.W. Niessen & D.W.J. Dippel (2013). Cost-effectiveness of two endovascular treatment strategies vs intravenous thrombolysis. Acta Neurologica Scandinavica, 127, 351-359. doi: 10.1111/ane.12065
    • K.M. Goor, T. Plochg, H. Lemij, E. van Sprundel, M.A. Koopmanschap & N.S. Klazinga (2013). Why a successful task substitution in glaucoma care could not be transferred from a hospital setting to a primary care setting: a qualitative study. Implementation Science, 8 (14), 1-10. doi: 10.1186/1748-5908-8-14
    • C.A.M. de Meijer, M.A. Koopmanschap, O.A. O'Donnell & E.K.A. van Doorslaer (2013). Looking beyond the average through decomposition of the full distribution. Journal of Health Economics, 32 (1), 88-105. doi: 10.1016/j.jhealeco.2012.10.009
    • K. Freijer, S.S. Tan, M.A. Koopmanschap, J.M.M. Meijers, R. Halfens & M.J.C. Nuijten (2013). The economic costs of disease related malnutrition. Clinical Nutrition, 32 (1), 136-141. doi: 10.1016/j.clnu.2012.06.009
    • P. Makai, M.A. Koopmanschap, W.B.F. Brouwer & A.P. Nieboer (2013). A validation of the ICECAP-O in a population of post-hospitalized older people in the Netherlands. Health and Quality of Life Outcomes, 11 (57). doi: 10.1186/1477-7525-11-57
    • C.A.M. de Meijer, I.M. Majer, M.A. Koopmanschap & P.H.M. van Baal (2012). Forecasting Lifetime and Aggregate Long-term Care Spending Accounting for Changing Disability Patterns. Medical Care, 50 (8), 722-729. doi: 10.1097/MLR.0b013e31824ebddc
    • J. Hermans, M.A. Koopmanschap, S.M.A. Bierma-Zeinstra, J.H. van Linge, J.A.N. Verhaar, M. Reijman & A. Burdorf (2012). Productivity Costs and Medical Costs Among Working Patients With Knee Osteoarthritis. Arthritis Care & Research, 64 (6), 853-861. doi: 10.1002/acr.21617
    • I. Cleemput, M.G. Franken, M.A. Koopmanschap & M. le Polain (2012). EUROPEAN DRUG REIMBURSEMENT SYSTEMS' LEGITIMACY: FIVE-COUNTRY COMPARISON AND POLICY TOOL. International Journal of Technology Assessment in Health Care, 28 (4), 358-366. doi: 10.1017/S0266462312000529
    • P. Makai, W.B.F. Brouwer, M.A. Koopmanschap & A.P. Nieboer (2012). Capabilities and quality of life in Dutch psycho-geriatric nursing homes: an exploratory study using a proxy version of the ICECAP-O. Quality of Life Research, 21, 801-812. doi: 10.1007/s11136-011-9997-1
    • M.G. Franken, M. le Polain, I. Cleemput & M.A. Koopmanschap (2012). SIMILARITIES AND DIFFERENCES BETWEEN FIVE EUROPEAN DRUG REIMBURSEMENT SYSTEMS. International Journal of Technology Assessment in Health Care, 28 (4), 349-357. doi: 10.1017/S0266462312000530
    • M.A. Koopmanschap (2012). Generic medicine pricing: on track in Europe? GaBi Journal, 1, 5-5.
    • J.C. Bouvy, M.A. Koopmanschap & H. Schellekens (2012). Value for money of drug regulation. Expert review of pharmacoeconomics & outcomes research, 12 (3), 247-249. doi: 10.1586/erp.12.18
    • J.C. Bouvy, M.A. Koopmanschap, R.R. Shah & H. Schellekens (2012). The Cost-Effectiveness of Drug Regulation: The Example of Thorough QT/QTc Studies. Clinical Pharmacology & Therapeutics, 91 (2), 281-288. doi: 10.1038/clpt.2011.224
    • C.A.M. De Meijer, M. Majer, M.A. Koopmanschap & P.H.M. van Baal (2012). Forecasting Lifetime and Aggregate Long-term Care Spending - Accounting for Changing Disability Patterns. Medical Care, 50 (8), 722-729. doi: 10.1097/MLR.0b013e31824ebddc
    • H.M. Krol, J. Papenburg, M.A. Koopmanschap & W.B.F. Brouwer (2011). Do Productivity Costs Matter? Pharmacoeconomics (Print), 7, 601-619.
    • P.P. van Es, P.A.J. Luijsterburg, J. Dekker, M.A. Koopmanschap, A.M. Bohnen, J.A.N. Verhaar, B.W. Koes & S.M.A. Bierma-Zeinstra (2011). Cost-effectiveness of exercise therapy versus general practitioner care for osteoarthritis of the hip: design of a randomised clinical trial. BMC Musculoskeletal Disorders, 12 (232), 1-7. doi: 10.1186/1471-2474-12-232
    • C.A.M. de Meijer, M.A. Koopmanschap, T.M. Bago d'Uva & E.K.A. van Doorslaer (2011). Determinants of long-term care spending: Age, time to death or disablility? Journal of Health Economics, 30 (2), 425-438. doi: 10.1016/j.jhealeco.2010.12.010
    • T.I.J. van den Berg, S. Robroek, J. Plat, M.A. Koopmanschap & A. Burdorf (2011). The importance of job control for workers with decreased work ability to remain productive at work. International Archives of Occupational and Environmental Health, 84 (6), 705-712. doi: 10.1007/s00420-010-0588-1
    • P. Makai, M.A. Koopmanschap, R.A. Bal & A.P. Nieboer (2010). Cost-effectiveness of a pressure ulcer quality collaborative. Cost Effectiveness and Resource Allocation, 8 (11), 1-31. doi: 10.1186/1478-7547-8-11
    • S.A. Baeten, N.J.A. van Exel, M. Dirks, M.A. Koopmanschap, D.W.J. Dippel & L.W. Niessen (2010). Lifetime health effects and medical costs of integrated stroke services - a non-randomized controlled cluster-trial based life table approach. Cost Effectiveness and Resource Allocation, 8 (21), 1-10. doi: 10.1186/1478-7547-8-21
    • S.S. Tan, R. van Linschoten, M. van Middelkoop, B.W. Koes, S.M.A. Bierma-Zeinstra & M.A. Koopmanschap (2010). Cost-utility of exercise therapy in adolescents and young adults suffering from the patellofemoral pain syndrome. Scandinavian Journal of Medicine & Science in Sports, 20 (4), 568-579. doi: 10.1111/j.1600-0838.2009.00980.x
    • M.A. Koopmanschap, E.A. Stolk & A.H.E. Koolman (2010). Dear policy maker: Have you made up your mind? A discrete choice experiment among policy makers and other health professionals. International Journal of Technology Assessment in Health Care, 26 (2), 198-204. doi: 10.1017/S0266462310000048
    • K.M. Goor, E. van Sprundel, H.G. Lemij, T. Plochg, N.S. Klazinga & M.A. Koopmanschap (2010). Cost-effectiveness of monitoring glaucoma patients in shared care: an economic evaluation alongside a randomized controlled trial. Bmc Health Services Research, 10 (312), 1-11. doi: 10.1186/1472-6963-10-312
    • C.A.M. de Meijer, W.B.F. Brouwer, M.A. Koopmanschap, B. van den Berg & N.J.A. van Exel (2010). The value of informal care-A further investigation of the feasibility of contingent valuation in informal caregivers. Health Economics, 19, 755-771. doi: 10.1002/hec.1513
    • M. van Duijn, M.J.C. Eijkemans, B.W. Koes, M.A. Koopmanschap, K. Burton & A. Burdorf (2010). The effects of timing on the cost-effectiveness of interventions for workers on sick leave due to low back pain. Occupational and Environmental Medicine, 67 (11), 744-750. doi: 10.1136/oem.2009.049874
    • C.A.M. de Meijer, M.A. Koopmanschap, A.H.E. Koolman & E.K.A. van Doorslaer (2009). The Role of Disability in Explaining Long-Term Care Utilization. Medical Care, 47 (11), 1156-1163. doi: 10.1097/MLR.0b013e3181b69fa8
    • F. Smit, G. Willemse, P. Meulenbeek, M.A. Koopmanschap, A.J.L.M. van Balkom, P. Spinhoven & P. Cuijpers (2009). Cost Effectiveness and Resource Allocation. Preventing panic disorder: cost-effectiveness analysis alongside a pragmatic randomised trial. BioMed Central, 7 (8), 1-12.
    • N.J.A. van Exel, A. Bobinac, M.A. Koopmanschap & W.B.F. Brouwer (2008). The invisible hands made visible: Recognizing the value of informal care in health care decision making. Expert review of pharmacoeconomics & outcomes research, 8 (6), 557-561. doi: 10.1586/14737167.8.6.557
    • M.A. Koopmanschap, N.J.A. van Exel, B. van den Berg & W.B.F. Brouwer (2008). An overview of methods and applications to value informal care in economic evaluations of healthcare. Pharmacoeconomics (Print), 26 (4), 269-280. doi: 10.2165/00019053-200826040-00001
    • B. van den Berg, M.J. Al, N.J.A. van Exel, M.A. Koopmanschap & W.B.F. Brouwer (2008). Economic valuation of informal care: conjoint analysis applied in a heterogeneous population of informal caregivers. Value in Health, 11 (7), 1041-1050. doi: 10.1111/j.1524-4733.2008.00357.x
    • M.A. Goossensen, P. Zijlstra & M.A. Koopmanschap (2007). Measuring shared decision making processes in psychiatry: Skills versus patient satisfaction. Patient Education and Counseling, 67, 50-56. doi: 10.1016/j.pec.2007.01.017
    • N.J.A. van Exel, A. Bobinac, M.A. Koopmanschap & W.B.F. Brouwer (2007). Providing informal care: a burden and a blessing. Health and Ageing, 16, 10-13.
    • L.W. Niessen, E.W.M. Grijseels, M.A. Koopmanschap & F.F.H. Rutten (2007). Economic analysis for clinical practice - the case of 31 national consensus guidelines in the Netherlands. Journal of Evaluation in Clinical Practice, 13 (1), 68-78. doi: 10.1111/j.1365-2753.2006.00662.x
    • B. van den Berg, W.B.F. Brouwer, N.J.A. van Exel, M.A. Koopmanschap, G. van den Bos & F.F.H. Rutten (2006). Economic valuation of informal care: Lessons from the application of the oppurtunity costs and proxy good methods. Social Science & Medicine, 62, 835-845. doi: 10.1016/j.socscimed.2005.06.046
    • N.J.A. van Exel, M. Moree, M.A. Koopmanschap, T. Scheuder Goedheijt & W.B.F. Brouwer (2006). Respite care- An explorative study of demand and use in Dutch informal caregivers. Health Policy, 78, 194-198. doi: 10.1016/j.healthpol.2005.11.002
    • N.J.A. van Exel, M.A. Koopmanschap, J. Mcdonnell, C.R. Chapple, R. Berges & F.F.H. Rutten (2006). Medical Consumption and Costs during a One-Year Follow-up of Patients with LUTS Suggestive of BPH in Six European Countries: Report of the TRIUMPH Study. European Urology, 49, 92-102. doi: 10.1016/j.eururo.2005.09.016
    • M.E. Smit, G. Willemse, M.A. Koopmanschap, S. Onrust, P. Cuijpers & A.J. Beekman (2006). Cost-effectiveness of preventing depression in primary care patients. British Journal of Psychiatry, 188, 330-336.
    • N.J.A. van Exel, W.B.F. Brouwer, B. van den Berg & M.A. Koopmanschap (2006). With a little help from an anchor; Discussion and evidence of anchoring effects in contigent valuation. Journal of Socio-economics, 35, 836-853.
    • C. Boersma, B. Radeva, M.A. Koopmanschap, A. Voors & M.J. Postma (2006). Economic evaluation of valsartan in patients with chronic heart failure: results from Val-HeFT adapted to The Netherlands. Journal of Medical Economics, 9, 121-131.
    • R. Linschoten, M. van Middelkoop, M.Y. Berger, E.M. Heintjes, M.A. Koopmanschap, J.A.N. Verhaar, B.W. Koes & S.M.A. Bierma-Zeinstra (2006). The PEX study - Exercise therapy for patellofemoral pain syndrome: design of a randomized clinical trial in general practice and sports medicine [ISRCTN83938749]. BioMed Central, 7. doi: 10.1186/1471-2474-7-31
    • B. van der Berg, W. Brouwer, N.J.A. van Exel & M.A. Koopmanschap (2005). Economic valuation of informal care: the contingent valuation method applied to informal caregiving. Health Economics, 14 (2), 169-183. doi: 10.1002/hec.893
    • K. Jacob-Tacken, M.A. Koopmanschap, W.J. Meerding & J.L. Severens (2005). Correcting for compensating mechanisms related to productivity costs in economic evaluations of health care programmes. Health Economics, 14 (5), 435-443. doi: 10.1002/hec.948
    • M.A. Koopmanschap (2005). PRODISQ: a modular questionnaire on productivity and disease for economic evaluation studies. Expert review of pharmacoeconomics & outcomes research, 5, 23-28. doi: 10.1586/14737167.5.1.23
    • M.A. Koopmanschap, A. Burdorf, K. Jacob, W.J. Meerding, W.B.F. Brouwer & J.L. Severens (2005). Productivity and health in economic evaluation; setting the research agenda. Pharmacogenetics, 23, 47-54.
    • N.J.A. van Exel, M.A. Koopmanschap, B. van der Berg, W.B.F. Brouwer & G. van den Bos (2005). Burden of informal caregiving for stroke patients - Identification of caregivers at risk of adverse health effects. Cerebrovascular Diseases, 19 (1), 11-17. doi: 10.1159/000081906
    • W.B.F. Brouwer & M.A. Koopmanschap (2005). The friction-cost method - Replacement for nothing and leisure for free? Pharmacoeconomics (Print), 23 (2), 105-111. doi: 10.2165/00019053-200523020-00002
    • M.A. Koopmanschap, W.B.F. Brouwer, L. van Roijen & N.J.A. van Exel (2005). Influence of waiting time on cost-effectiveness. Social Science & Medicine, 60 (11), 2501-2504. doi: 10.1016/j.socscimed.2004.11.022
    • B. van der Berg, M.J. Al, W. Brouwer, N.J.A. van Exel & M.A. Koopmanschap (2005). Economic valuation of informal care: The conjoint measurement method applied to informal caregiving. Social Science & Medicine, 61 (6), 1342-1355. doi: 10.1016/j.socscimed.2005.01.029
    • W.B.F. Brouwer, N.J.A. van Exel, B. van der Berg, G. van den Bos & M.A. Koopmanschap (2005). Process utility from providing informal care: the benefit of caring. Health Policy, 74 (1), 85-99. doi: 10.1016/j.healthpol.2004.12.008
    • M.B. Hoeijenbos, T. Bekkering, L. Lamers, E. Hendriks, M. van Tulder & M.A. Koopmanschap (2005). Cost-effectiveness of an active implementation strategy for the Dutch physiotherapy guideline for low back pain. Health Policy, 75 (1), 85-98. doi: 10.1016/j.healthpol.2005.02.008
    • G.E. Bekkering, M.W. van Tulder, E.J.M. Hendriks, M.A. Koopmanschap, D.L. Knol, L.M. Bouter & R.A.B. Oostendorp (2005). Implementation of clinical guidelines on physical therapy for patients with low back pain: Randomized trial comparing patient outcomes after a standard and active implementation strategy. Physical Therapy, 85 (6), 544-555.
    • M.A. Koopmanschap, A. Burdorf, K. Jacob, W.J. Meerding, W. Brouwer & J.L. Severens (2005). Measuring productivity changes in economic evaluation - Setting the research agenda. Pharmacoeconomics (Print), 23 (1), 47-54. doi: 10.2165/00019053-200523010-00004
    • N.J.A. van Exel, M.A. Koopmanschap, W.J.M. Scholte op Reimer, L.W. Niessen & R. Huijsman (2005). Cost-effectiveness of integrated stroke services. QJM. Quarterly Journal of Medecine (Association of Physicians), 98 (6), 415-425. doi: 10.1093/qjmed/hci065
    • W.J. Meerding, W. Ijzelenberg, M.A. Koopmanschap, J.L. Severens & A. Burdorf (2005). Health problems lead to considerable productivity loss at work among workers with high physical load jobs. Journal of Clinical Epidemiology, 58 (5), 517-523. doi: 10.1016/j.jclinepi.2004.06.016
    • N.J.A. van Exel, W.J.M. Scholte op Reimer & M.A. Koopmanschap (2004). Assessment of post-stroke quality of life in cost-effectiveness studies: The usefulness of the Barthel Index and the EuroQoL-5D. Quality of Life Research, 13, 427-433. doi: 10.1023/B:QURE.0000018496.02968.50
    • M.A. Koopmanschap, N.J.A. van Exel, G. van den Bos, B. van den Berg & W.B.F. Brouwer (2004). The desire for support and respite care:preferences of Dutch informal caregivers. Health Policy, 68, 309-320. doi: 10.1016/j.healthpol.2003.10.002
    • N.J.A. van Exel, B. van den Berg, M.A. Koopmanschap & W.B.F. Brouwer (2004). Mantelzorg: een goed om te waarderen. Nederlands Tijdschrift voor Geneeskunde, 82, 236-242.
    • N.J.A. van Exel, W.J.M. Scholte op Reimer, W.B.F. Brouwer, B. van den Berg, M.A. Koopmanschap & G. van den Bos (2004). Instruments for assessing the burden of informal caregiving for stroke patients in clinical practice: a comparison of CSI, CRA, SCQ and self-rated burden. Clinical Rehabilitation, 18, 203-214. doi: 10.1191/0269215504cr723oa
    • B. van den Berg, W.B.F. Brouwer & M.A. Koopmanschap (2004). Economic valuation of informal care. European Journal of Health Economics (HEPAC), 5, 36-45.
    • N.J.A. van Exel, M.A. Koopmanschap, J.D.H. van Wijngaarden & W.J.M. Scholte op Reimer (2003). Costs of stroke and stroke services: determinants of patient costs and a comparison of costs of regular care and care organised in stroke services. Cost Effectiveness and resource allocation. Cost Effectiveness and Resource Allocation, 1, 1-11.
    • T. Adam, D.B. Evans & M.A. Koopmanschap (2003). Cost-effeciveness analysis: can we reduce variability in costing methods? International Journal of Technology Assessment in Health Care, 19 (2), 407-420.
    • J.B. Oostenbrink, T. Buijs - van der Woude, M. van Agthoven, M.A. Koopmanschap & F.F.H. Rutten (2003). Unit costs of inpatient hospital days. Pharmacoeconomics (Print), 21 (4), 263-271. doi: 10.2165/00019053-200321040-00004
    • M.A. Koopmanschap & F.F.H. Rutten (2003). The drug budget silo mentality: the Dutch case. Value in Health, 6 (1), 46-51. doi: 10.1046/j.1524-4733.6.s1.5.x
    • M.A. Koopmanschap (2002). Coping with type II diabetes: the patient's perspective. Diabetologia, 45, 18-22.
    • W.K. Redekop, M.A. Koopmanschap, E.A. Stolk, F.F.H. Rutten, B.H.R. Wolffenbuttel & L.W. Niessen (2002). Health related quality of life and treatment satisfaction in Dutch patients with type 2 diabetes. Diabetes Care, 25 (3), 458-463. doi: 10.2337/diacare.25.3.458
    • W.K. Redekop, M.A. Koopmanschap, F.F.H. Rutten, B.H.R. Wolffenbuttel, E.A. Stolk & L.W. Niessen (2002). Resource consumption and costs in Dutch patients with Type II diabetes mellitus. Results from 29 general practices. Diabetic Medicine, 19, 246-253. doi: 10.1046/j.1464-5491.2002.00654.x
    • J.B. Oostenbrink, M.A. Koopmanschap & F.F.H. Rutten (2002). Standardisation of costs. The Dutch manual for costing in economic evaluation. Pharmacoeconomics (Print), 20 (7), 443-454.
    • W.B.F. Brouwer, N.J.A. van Exel, M.A. Koopmanschap & F.F.H. Rutten (2002). Productivity losses before and after absence: as important as common? Health Policy, 61, 173-187.
    • F.F.H. Rutten, H. Bleichrodt, W.B.F. Brouwer, M.A. Koopmanschap & F.T. Schut (2001). Book review Handbook of health economics. Journal of Health Economics, 20, 855-879.
    • J. Mcdonnell, J.J. van Busschbach, E. Kok, N.J.A. van Exel, E.A. Stolk, M.A. Koopmanschap & F.F.H. Rutten (2001). Lower urinary tract symptoms suggestive of benign prostatic obstruction- Triumph: health-economical analysis. European Urology, 39 (supplement), 37-41.
    • M.A. Koopmanschap & L.M. Lamers (2000). Chronic conditions, psychological distress and the use of psychoactive medications. Journal of Psychosomatic Research, 48, 115-123.
    • N. van Os, L.W. Niessen, M.A. Koopmanschap & J. van der Lei (2000). Gedetailleerde raming van de maatschappelijke kosten van diabetes mellitus. Nederlands Tijdschrift voor Geneeskunde, 144 (18), 842-846.
    • D. Curran, N.K. Aaronson, B. Standaert, G. Molenberghs, P. Therasse, A. Ramirez, M.A. Koopmanschap, H. Erder & M.J. Piccart (2000). Summary measures and statistics in the analysis of quality of life data: an example from an EORTC-NCIC-SAKK locally advanced breast cancer study. European Journal of Cancer, 36, 834-844. doi: 10.1016/S0959-8049(00)00056-3
    • N. van Os, L.W. Niessen, M.A. Koopmanschap & J. van der Lei (2000). Gedetailleerde raming van de maatschappelijke kosten van diabetes mellitus. Nederlands Tijdschrift voor Geneeskunde, 144 (18), 842-846.
    • W.B.F. Brouwer & M.A. Koopmanschap (2000). On the economic foundations of CEA. Ladies and gentlemen, take your positions! Journal of Health Economics, 19, 439-459.
    • W.B.F. Brouwer & M.A. Koopmanschap (2000). On the economic foundations of CEA. Ladies and gentlemen, take your positions! Journal of Health Economics, 19, 439-459.
    • W.B.F. Brouwer, N.J.A. van Exel, M.A. Koopmanschap & F.F.H. Rutten (1999). The valuation of informal care in economic appraisal. International Journal of Technology Assessment in Health Care, 15 (1), 147-160.
    • W.B.F. Brouwer, M.A. Koopmanschap & F.F.H. Rutten (1999). Productivity losses without absence. Health Policy, 13-27.
    • M.A. Koopmanschap, J.J. Polder, W.J. Meerding, L. Bonneux & P.J. van der Maas (1998). Costs of Dementia in the Netherlands. Health Economics Approaches to Dementia, 207-215.
    • W.J. Meerding, L. Bonneux, J.J. Polder, M.A. Koopmanschap & P.J. van der Maas (1998). Demographic and epidemiological determinants of healthcare costs in Netherlands: cost of illness study. British Medical Journal, 317, 111-115.
    • J.J. Polder, W.J. Meerding, M.A. Koopmanschap, L. Bonneux & P.J. van der Maas (1998). Kosten van ziekten in Nederland in 1994; grootste zorgverbruik door hoge leeftijd en beperkende aandoeningen. Nederlands Tijdschrift voor Geneeskunde, 142 (28), 1607-1611.
    • M.A. Koopmanschap & F.F.H. Rutten (1998). berekening van kosten van zorg. TSG, 76 (2), 83-88.
    • C.R. Touw & M.A. Koopmanschap (1998). Kosten van Psoriasis in Nederland. Nederlands Tijdschrift voor Dermatologie & Venereologie, 8, 215-219.
    • W.B.F. Brouwer, M.A. Koopmanschap & F.F.H. Rutten (1998). Patient and informal caregiver time in cost- effectiveness analysis. International Journal of Technology Assessment in Health Care, 14 (3), 505-513.
    • M.J. Al, M.A. Koopmanschap, P.J. van Enckevort, A. Geertsma, W. van der Bij, W.J. Boer & E.M. ten Vergert (1998). Coast- effectiveness of lung transplantation in the Netherlands. Chest, 113 (1), 124-130.
    • F.F.H. Rutten, J.J. van Busschbach, B.A. van Hout, M.A. Koopmanschap & B.C. Michel (1998). Economische evaluatie van gezondheidsprogramma's. TSG, 76, 74-82.
    • M.A. Koopmanschap (1998). Paars 2 uit de zorgen met twee procent? Tijdschrift voor Sociale Gezondheidszorg, 76 (8), 417-418.
    • M.A. Koopmanschap (1998). Cost- of- Illness Studies. Pharmacoeconomics (Print), 14 (2), 143-148. doi: 10.2165/00019053-199814020-00001
    • W.J. Meerding, L. Bonneux, J.J. Polder, M.A. Koopmanschap & P.J. van der Maas (1998). Demographic and epidemiological determinants of healthcare costs in Netherlands: cost of illness study. British Medical Journal, 317, 111-115.
    • J.J. Polder, W.J. Meerding, M.A. Koopmanschap, L. Bonneux & P.J. van der Maas (1998). Kosten van ziekten in Nederland in 1994; grootste zorgverbruik door hoge leeftijd en beperkende aandoeningen. Nederlands Tijdschrift voor Geneeskunde, 142 (28), 1607-1611.
    • P.J. van Enckevort, E.M. TenVergert, G.J. Bonsel, A. Geertsma, W. van der Bij, W.J. Boer, M.A. Koopmanschap, M.J. Al & F.F.H. Rutten (1998). Technology Assessment of the Dutch lung transplantation program. International Journal of Technology Assessment in Health Care, 14 (2), 344-356.
    • E.M. TenVergert, P.J. van Enckevort, A. Geertsma, M.A. Koopmanschap, W. van der Bij & W.J. Boer (1998). Evaluatie van het Groningse longtransplantatieprogramma: overleving, kwaliteit van leven en kosteneffectiviteit. Nederlands Tijdschrift voor Geneeskunde, 142 (17), 957-962.
    • M.A. Koopmanschap & W.B.F. Brouwer (1998). Indirect Costs and Costing Informal Care. Health Economics Approaches to Dementia, 245-256.
    • W.J. Meerding, J.P. Polder, L. Bonneux, M.A. Koopmanschap & P.J. van der Maas (1998). Health- care costs of ageing. Lancet (UK), 351, 140-140.
    • J.J. Polder, W.J. Meerding, M.A. Koopmanschap, L. Bonneux & P.J. van der Maas (1997). De stijgende kosten van de gezondheidszorg. Economisch-Statistische Berichten, 82 (4120), 702-705.
    • D.H.C.M. Stolker, G. van den Bos, N.S. Klazinga, M.A. Koopmanschap & M.C.M. Senten (1997). 'Stroke service': een bewezen dienst? Tijdschrift voor Sociale Gezondheidszorg, 75 (8), 518-519.
    • M.A. Koopmanschap, F.F.H. Rutten, B.M. van Ineveld & L. van Roijen (1997). Reply to Johanneson's and Karlsson's comment. Journal of Health Economics, 257-259.
    • M.A. Koopmanschap (1997). Volksgezondheid Toekomst Verkenning 1997: van zorgbehoefte naar zorggebruik. Tijdschrift voor Sociale Gezondheidszorg, 75 (6), 366-367.
    • B.M. van Ineveld & M.A. Koopmanschap (1997). Farmaco-economie: hobbels en valkuilen van kostenberekeningen. Ziekenhuisfarmacie, 1 (1), 48-51.
    • P.J. van Enckevort, M.A. Koopmanschap, E.M. TenVergert, A. Geertsma, W. van der Bij, W.J. Boer & F.F.H. Rutten (1997). Lifetime costs of lung transplantation of incremental costs. Health Economics, 479-489.
    • J. van den Bos & M.A. Koopmanschap (1997). Beroerte: een multidisiplinair vraagstuk. Tijdschrift voor Sociale Gezondheidszorg, 75 (8), 465-466.
    • W.B.F. Brouwer, M.A. Koopmanschap & F.F.H. Rutten (1997). Productivity costs measurement through quality of life? A response to the recommendation of the Washington Panel. Health Economics, 253-259.
    • W.B.F. Brouwer, M.A. Koopmanschap & F.F.H. Rutten (1997). Productivity costs in cost-effectiveness analysis numerator or denominator: a further discussion. Health Economics, 511-514.
    • M.A. Koopmanschap & F.F.H. Rutten (1996). Indirect Costs; The Consequence of Production Loss or Increased Costs of Production. Medical Care, 34 (12), DS59-DS68.
    • L. van Roijen, M.L. Bot, M.A. Koopmanschap, G.J. Bonsel & F.F.H. Rutten (1996). Labor and Health Status in Economic Evaluation of Health Care. International Journal of Technology Assessment in Health Care, 12 (3), 405-415.
    • M.A. Koopmanschap & F.F.H. Rutten (1996). A Practical Guide for Calculating Indirect Costs of Disease. Pharmacoeconomics (Print), 5 (10), 460-466.
    • M. van Ballegooijen, M.A. Koopmanschap & J.D.F. Habbema (1995). The Management of Cervical Intra-epithelial Neoplasia (CIN): Extensiveness and Costs in The Netherlands. European Journal of Cancer, 31A (10), 1672-1676. doi: 10.1016/0959-8049(95)00243-C
    • L. van Roijen, M.A. Koopmanschap, F.F.H. Rutten & P.J. van der Maas (1995). Indirect costs of disease; an international comparison. Health Policy, 33, 15-29. doi: 10.1016/0168-8510(94)00704-I
    • M.A. Koopmanschap, F.F.H. Rutten, B.M. van Ineveld & L. van Roijen (1995). The friction cost method for measuring indirect costs of disease. Journal of Health Economics, 14, 171-189. doi: 10.1016/0167-6296(94)00044-5
    • L. van Roijen, M.L. Essink-Bot, M.A. Koopmanschap, B.C. Michel & F.F.H. Rutten (1995). Societal Perspective on the Burden of Migraine in The Netherlands. Pharmacoeconomics (Print), 7 (2), 170-179.
    • M.A. Koopmanschap (1995). Arbeidsverdeling. Tijdschrift voor Sociale Gezondheidszorg, 73 (5), 266-266.

  • Professional Publication (13)

    • M.A. Koopmanschap, J.L. Severens & M.G. Franken (2012). Internationale aspecten bij besluitvorming inzake geneesmiddelenvergoeding. Economisch-Statistische Berichten, 97 (4644S), 36-39.
    • A. Steenhoek & M.A. Koopmanschap (2010). Doelmatigheid dure medicijnen afwegen. Medisch Contact, 65 (35), 1709-1711.
    • A. Steenhoek, M.A. Koopmanschap, M.G. Franken & F.F.H. Rutten (2010). Nieuwe geneesmiddelen: niet goed, geld terug? Nederlands Tijdschrift voor Geneeskunde, 154 (A2042), 1-5.
    • M.A. Koopmanschap & A. Steenhoek (2007). Kosten voor dure medicijnen rijzen de pan uit Groter gebruik: lagere prijs. PW, 142, 1-1.
    • N.J.A. van Exel, M. Moree, M.A. Koopmanschap, T. Schreuder Goedheijt & W.B.F. Brouwer (2006). Respijtzorg: Een verkenning van behoefte en gebruik onder 273 mantelzorgers. TSG, 84 (2), 90-99.
    • W.K. Redekop & M.A. Koopmanschap (2004). Economische aspecten van polyfarmacie bij diabetes. CBO, 8-22.
    • N.J.A. van Exel, M.A. Koopmanschap & W.B.F. Brouwer (2003). Kostbaar ontslag, korte verpleegduur brengt mantelzorgers in de problemen. Medisch Contact, 58, 1272-1274.
    • R. Huijsman, W.J.M. Scholte op Reimer, N.S. Klazinga, J.D.H. van Wijngaarden, N.J.A. van Exel, C. van Putte-Boon, M.A. Koopmanschap & L.W. Niessen (2002). Stroke service: Edisse-studie onderbouwt noodzaak van landelijke implementatie van CVA-ketenzorg. Kwaliteit in beeld, 12, 8-12.
    • N. Feenstra, G.E.H.M. Rutten, M.A. Koopmanschap & R.B. Jansen (2000). Een gezondheidseconomische uitdaging; analyse van diabetes mellitus type 2. Medisch Contact, 55 (6), 209-212.
    • M. Berg, W. Brouwer & M.A. Koopmanschap (2000). Recht op thuiszorg; hoe zijn de wachttijden op korte termijn te reduceren? Medisch Contact, 55 (3), 93-96.
    • B. van den Berg, W.B.F. Brouwer & M.A. Koopmanschap (2000). Recht op thuiszorg; hoe zijn de wachttijden op korte termijn te reduceren? Medisch Contact, 55 (3), 93-96.
    • J.J. Polder, W.J. Meerding, M.A. Koopmanschap, L. Bonneux & P.J. van der Maas (1997). De stijgende kosten van de gezondheidszorg. Economisch-Statistische Berichten, 82 (4120), 702-705.
    • B.M. van Ineveld & M.A. Koopmanschap (1995). De hobbels en valkuilen van de kostenberekeningen binnen de farmaco-economie. Nederlands Tijdschrift voor Farmacotherapie, 1 (2), 43-47.

• Part of book - Chapter (16)

  • Scholarly Publication (12)

    • M.A. Koopmanschap, A. Burdorf & F.J.B. Lötters (2013). Work Absenteeism and Productivity Loss at Work. In P. Loisel & J.R. Anema (Eds.), Handbook of Work Disability (pp. 31-41). New York: Springer
    • M.A. Koopmanschap & F.F.H. Rutten (2005). Country report; results from a survey among decision-makers in the Netherlands. In S Eberhardt, C Stoklossa & JM von der Schulenburg (Eds.), Euromet 2004: the influence of economic evaluation studies on health care decision-making; a European survey (pp. 155-170). Amsterdam: IOS Press
    • L. Gulacsi, F.F.H. Rutten, M.A. Koopmanschap & M. Költsegszamitas (2005). Egeszseg-Gazdasagtan. In G Laszio (Ed.), Medicina (pp. 191-262). Budapest: Könyvkiado
    • M.A. Koopmanschap & W.B.F. Brouwer (2001). Controversial costs in guidelines. In -- -- (Ed.), Economic evaluation; from theory to practice (pp. 129-143). --: --
    • W.B.F. Brouwer, F.F.H. Rutten & M.A. Koopmanschap (2001). Costing in economic evaluations. In M. Drummond & A. McGuire (Eds.), Economic evaluation in health care; merging theory with practice (pp. 68-93). Oxford: Oxford University press
    • M.A. Koopmanschap (1999). Estimating the indirect costs of smoking using the friction cost method. In C. Jeanrenaud & N. Soguel (Eds.), Valuing the cost of smoking; assessment methods, risk perception and policy options (pp. 49-59). Boston, Dordrecht, London: Kluwer Academic Publishers
    • M.A. Koopmanschap (1999). Cost-of-Illness Studies: Useful for Health Policy? In G. Mallarkey (Ed.), Economic Evaluation in Healthcare (pp. 53-58). Hong Kong: Adis International
    • H. Bleichrodt & M.A. Koopmanschap (1999). Economische evaluatie. In R. Lapre, F. Rutten & E. Schut (Eds.), Algemene economie van de gezondheidszorg (pp. 252-272). Maarssen: Elsevier/De Tijdstroom
    • M.A. Koopmanschap, J.J. Polder, W.J. Meerding, L. Bonneux & P.J. van der Maas (1998). Costs of dementia in the Netherlands. In A. Wimo, B. Jönsson, G. Karlsson & B. Winblad (Eds.), Health economics of dementia (pp. 207-215). Chichester: John Wiley & Sons
    • W.B.F. Brouwer, M.A. Koopmanschap & F.F.H. Rutten (1998). Patient and informal caregiver time in cost-effectiveness analysis. A response to the recommendations of the Washington Panel. In International journal of Technology Assessment in Health Care (14, 3) (pp. 505-513). Cambridge: Cambridge University press
    • W.B.F. Brouwer & M.A. Koopmanschap (1997). Kosten binnen en buiten de gezondheidszorg. In D Post & LJ Stokx (Eds.), Volksgezondheid Toekomst Verkenning: zorgbehoefte en zorggebruik (pp. 43-56). Utrecht: ELSEVIER / De Tijdstroom
    • M.A. Koopmanschap & F.F.H. Rutten (1995). Indirect costs in economic studies: Confronting the confusion. In C. Selby Smith & M.F. Drummond (Eds.), Economic Evaluation in Australian Health Care (pp. 58-67). Canberra: Australian Government Publishing Service

  • Professional Publication (4)

    • W.B.F. Brouwer & M.A. Koopmanschap (2010). Overige kosten binnen en buiten de gezondheidszorg. In M. Rutten-Van Mölken, F.F.H Rutten & C.A. Uyl-De Groot (Eds.), Van Kosten Tot Effecten Een Handleiding Voor Evaluatiestudies in De Gezondheidszorg (pp. 19-4). Maarssen: Elsevier Gezondheidszorg
    • W.B.F. Brouwer & M.A. Koopmanschap (2000). Overige kosten binnen en buiten de gezondheidszorg. In M.P.M.H. Rutten- van Mölken, J.J. van Busschbach & F.F.H. Rutten (Eds.), Van kosten tot effecten (pp. 43-62). Maarssen: Elsevier gezondheidszorg
    • F.F.H. Rutten, J.B. Oostenbrink & M.A. Koopmanschap (2000). Directe kosten van gezondheidszorg. In M.P.M.H. Rutten- van Mölken, J.J. van Busschbach & F.F.H. Rutten (Eds.), Van kosten tot effecten (pp. 31-42). Maarssen: Elsevier gezondheidszorg
    • J.J. Polder, W.J. Meerding, M.A. Koopmanschap, L. Bonneux, L.J. Stokx & P.J. van der Maas (1997). Kosten van ziekten binnen de gezondheidszorg. In D. Post & L.J. Stokx (Eds.), Volksgezondheid Toekomst Verkenning 1997 - Themarapport VI: Zorgbehoefte en zorggebruik (pp. 57-83). Maarssen: RIVM/Elsevier/De Tijdstroom

• Book editorship (1)

  • J.B. Oostenbrink, C.A.M. Boumans, M.A. Koopmanschap & F.F.H. Rutten (Ed.). (2004). Methoden en standaard kostprijzen voor economische evaluaties in de gezondhedszorg. --: Handleiding voor Kostenonderzoek 2004

• Report (11)

  • Scholarly Publication (2)

    • M. le Polain, M.G. Franken, M.A. Koopmanschap & I. Cleemput (2010). Drug reimbursement systems: international comparison and policy recommendations. (Extern rapport, KCE Reports, no 147C). Brussel: Federaal Kenniscentrum voor de gezondheidszorg - Centre fédéral d'expertise des soins de santé
    • M.A. Koopmanschap, C.A.M. de Meijer, B. Wouterse & J. Polder (2010). Determinants of Health Care Expenditure in an Aging Society. (Extern rapport). Tilburg: Netspar

  • Professional Publication (9)

    • K.M. Goor, N.S. Klazinga, M.A. Koopmanschap, H.G. Lemij, T. Plochg & E. van Sprundel (2010). Monitoring of stable glaucoma patients. (Extern rapport). Rotterdam: eigen beheer iBMG/EUR
    • M.J. van den Berg, M.A. Koopmanschap, D.H. de Bakker & R.A. Verheij (2007). Samenwerking en substitutie in Gezondheidscentrum West Evaluatie van de eerste ervaringen met geïntegreerde eerstelijnszorg volgens het Menzis-model. (Extern rapport). Utrecht: Nivel
    • M.A. Goossensen, M.A. Koopmanschap, K.J. Grit, M. de Mul, A.H.E. Koolman & P. Zijlstra (2007). Evaluatie Proeftuin Farmacie Groningen. (Intern rapport). onbekend: Health policy and management (BMG)
    • R. Heijink, M.A. Koopmanschap & J.J. Polder (2006). International Comparison of Cost of Illness. (Extern rapport). Rotterdam: iBMG/IMTA Erasmus MC
    • R. Huijsman, N.S. Klazinga, W.J.M. Scholte op Reimer, J.D.H. van Wijngaarden, N.J.A. van Exel, C. van Putte-Boon, F.T. Prestholt, M.A. Koopmanschap & L.W. Niessen (2001). Beroerte, beroering en borging in de keten; resultaten van de Edisse-studie van drie regionale experimenten met stroke service. (Extern rapport). Den Haag/Rotterdam: Zon Mw/Erasmus MC
    • J.B. Oostenbrink, M.A. Koopmanschap & F.F.H. Rutten (2000). Handleiding voor kostenonderzoek; methoden en richtlijnprijzen voor economische evaluaties in de gezondheidszorg. (Extern rapport). Amstelveen: College voor zorgverzekeringen
    • J.J. Polder, W.J. Meerding, M.A. Koopmanschap, L. Bonneux & P.J. van der Maas (1997). Kosten van ziekten in Nederland 1994. (Intern rapport). :
    • J.J. Polder, W.J. Meerding, M.A. Koopmanschap, L. Bonneux & P.J. van der Maas (1997). Kosten van ziekten in Nederland 1994. (Intern rapport). :
    • M.A. Koopmanschap (1997). Kerncijfers maatschappelijke kosten van arbeidsomstandigheden in Nederland. (Intern rapport). :

• Supervised Theses (3)

  • K.M. Goor. Health Technology Assessment of health care innovations in Chronic Lymphocytic Leukaemia and Glaucoma Care: The value of mixed methods research. EUR Prom./coprom.: prof.dr. C.A. de Uyl-de Groot & dr. M.A. Koopmanschap.
  • C.A.M. de Meijer (2012, maart 1). Studies of Health and Long-Term Care Expenditure Growth in Aging Populations. EUR (220 pag.) (Rotterdam: Optima Grafische Communicatie) Prom./coprom.: dr. M.A. Koopmanschap.
  • T.M.S. Adam (2006, januari 13). Sources of Variability in Costing Methods; Implicatons for the Transferability of Cost-Effectiveness Results. EUR prof.dr. F.F.H. Rutten (263 pag.) (Enschede: PrintPartners Iskamp) Prom./coprom.: prof.dr. F.F.H. Rutten & dr. M.A. Koopmanschap.

Present position